^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    briquilimab (JSP191)

    i
    Other names: JSP191, AMG 191, AMG-191, JSP-191
    Associations

    News

    Trials
    Company:
    Amgen, Jasper Therap
    Drug class:
    c-KIT inhibitor
    Related drugs:
    Associations

    News

    Trials
    19d
    Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS. (PubMed, Blood)
    Based on preclinical data demonstrating the antibody clears hematopoietic stem and progenitor cells (HSPC) and myeloid malignant cells, we conducted a phase 1 trial examining briquilimab plus non-myeloablative fludarabine (flu) and total body irradiation (TBI) as conditioning for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing matched donor allogeneic hematopoietic cell transplantation (HCT)...Graft-versus-host disease prophylaxis consisted of tacrolimus, sirolimus, and mycophenolate mofetil...In summary, we demonstrate the feasibility, safety, and proof of concept of CD117 targeting with briquilimab as HCT conditioning for AML/MDS. The trial is registered at clinicaltrials.gov; using identifier: NCT04429191.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    sirolimus • fludarabine IV • briquilimab (JSP191)
    30d
    A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Jasper Therapeutics, Inc. | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Aug 2026
    Enrollment closed • Trial primary completion date
    |
    briquilimab (JSP191)
    2ms
    BEACON: Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) (clinicaltrials.gov)
    P1/2, N=88, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Apr 2026 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    briquilimab (JSP191)
    6ms
    SPOTLIGHT: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (clinicaltrials.gov)
    P1/2, N=27, Terminated, Jasper Therapeutics, Inc. | Trial completion date: Nov 2025 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Jul 2025; Enrollment was completed and primary efficacy endpoint was completed. Study was terminated before safety follow up was completed due to changes in company priorities and not related to safety concerns
    Trial completion date • Trial termination • Trial primary completion date
    |
    briquilimab (JSP191)
    6ms
    A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma (clinicaltrials.gov)
    P1, N=17, Terminated, Jasper Therapeutics, Inc. | N=30 --> 17 | Active, not recruiting --> Terminated; Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
    Enrollment change • Trial termination
    |
    briquilimab (JSP191)
    7ms
    Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=38 --> 7
    Enrollment closed • Enrollment change
    |
    briquilimab (JSP191)
    8ms
    A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    briquilimab (JSP191)
    8ms
    JSP191 Antibody Targeting Conditioning in SCID Patients (clinicaltrials.gov)
    P1/2, N=23, Terminated, Jasper Therapeutics, Inc. | N=40 --> 23 | Trial completion date: Jun 2028 --> Jul 2025 | Active, not recruiting --> Terminated; Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL7R (Interleukin 7 Receptor) • JAK3 (Janus Kinase 3) • RAG1 (Recombination Activating 1)
    |
    briquilimab (JSP191)
    10ms
    SPOTLIGHT: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    briquilimab (JSP191)
    12ms
    Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) (clinicaltrials.gov)
    P1, N=38, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Recruiting
    Enrollment open
    |
    briquilimab (JSP191)
    12ms
    JSP191 Antibody Targeting Conditioning in SCID Patients (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, Jasper Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL7R (Interleukin 7 Receptor) • JAK3 (Janus Kinase 3) • RAG1 (Recombination Activating 1)
    |
    briquilimab (JSP191)
    1year
    Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | N=72 --> 6 | Trial completion date: Mar 2033 --> Nov 2027 | Trial primary completion date: Sep 2032 --> Nov 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • sirolimus • briquilimab (JSP191)